摘要:
A radio and a transmit power control method in a radio system supporting a use of coding blocks in communication between a base station and user equipment is disclosed. The method comprises producing a measured SIR (signal-to-interference ratio) value and compares the measured SIR value with the target SIR value. Accordingly, the method also comprises determining the quality of the received coding blocks. The method also comprising storing samples of the differences between the measured SIR value and the target SIR value. The method also comprises adjusting the target SIR value based on the values of the samples of differences between the measured SIR value and the target SIR value and the quality of the received coding block. The method also comprises providing a transmit power control command based on the adjusted target SIR value to the user equipment.
摘要:
In various embodiments, a wavelength beam combining laser system includes a fast-axis collimation lens that is rotated with respect to a plurality of emitters in order to converge the emitted beams onto a dispersive element and/or reduce the size of the multi-wavelength output beam of the system.
摘要:
In various embodiments, wavelength beam combining laser systems incorporate fast-axis collimation lenses and slow-axis collimation lenses (either separately or as portions of a single hybrid lens) optically upstream of an optical rotation system to thereby reduce or minimize cross-talk in the combined output beam.
摘要:
In various embodiments, a laser apparatus includes top and bottom electrode mounts, a beam emitter between the electrode mounts, a fast axis collimation lens, an optical rotator, and a lens holder or lens mount positioning the lens and the optical rotator to intercept one or more beams emitted by the beam emitter.
摘要:
The invention provides novel immune regulatory oligonucleotides (IRO) as antagonist of TLRs and methods of use thereof. These IROs have unique sequences that inhibit or suppress TLR-mediated signaling in response to a TLR ligand or TLR agonist. The methods may have use in the prevention and treatment of cancer, an autoimmune disorder, airway inflammation, inflammatory disorders, infectious disease, skin disorders, allergy, asthma or a disease caused by a pathogen.
摘要:
The invention relates to the therapeutic use of novel stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides novel RNA-based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
摘要:
The invention relates to the therapeutic use of immunostimulatory oligonucleotides and/or immunomers in combination with chemotherapeutic agents to provide a synergistic therapeutic effect.
摘要:
Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR5. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR5 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR5 expression and for prevention or treatment of diseases wherein modulation of TLR5 expression would be beneficial are provided.
摘要:
Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR8. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR8 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR8 expression and for prevention or treatment of diseases wherein modulation of TLR8 expression would be beneficial are provided.
摘要:
Antisense oligonucleotide compounds, compositions and methods are provided for down regulating the expression of TLR7. The compositions comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7. The compositions may also comprise antisense oligonucleotides targeted to nucleic acids encoding TLR7 in combination with other therapeutic and/or prophylactic compounds and/or compositions. Methods of using these compounds and compositions for down-regulating TLR7 expression and for prevention or treatment of diseases wherein modulation of TLR7 expression would be beneficial are provided.